Image representing bacterial infections in the immune system
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Recce Pharmaceutical Ltd (ASS:RCE) has reached a milestone in its Phase II clinical trial to test the efficacy of its RECCE 327 topical gel for treatment of Acute Bacterial Skin and Skin Structure Infections (or ABSSSI) – with 20 of 30 total patients being dosed.

Data taken from the trial indicates the gel – also known as R327G – has yielded a strong effective response from participants, all of whom have reported positive outcomes after treatment, including total cure or notable improvement.

At the same time, no Serious Adverse Events (SAEs) have been reported for the gel.

Chief Medical Advisor Dr Alan W Dunton said all indicators boded well from the trial, and underpinned Recce’s success with development and assessment of R327G.

“These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies,” he said.

“The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase II trial.

“Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections.”

Recce shares moved up on the news, and at 12:51 AEDT, they were trading at 45 cents – a rise of 1.12% since the market opened.

Join the discussion: See what HotCopper users are saying about Recce and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

RCE by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: RBA keeps rates on hold amid sticky inflation | November 5, 2024

The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus…
The Market Online Video

Timing will be everything for ‘smashing’ Hot Stock tip Judo Capital Holdings

Australian bank Judo Capital Holdings (ASX:JDO), best known for its finance and credit for small and medium-sized businesses, is
The Market Online Video

‘We’re looking’: Nickel-rich Indonesia sounds graphite warning to Aus producers

Nickel-rich Indonesia muscles in on Australian graphite producers as the Southeast Asian country expands into downstream…
Confused man

Aussie inflation seemingly hit a 3 year low. So why’s the ASX200 red?

Headline inflation in Australia has fallen to 2.8%, and that officially takes us into the RBA's…